Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 56Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 29Neoplasm Metastasis 23Glioblastoma 23Colonic Neoplasms 23Rectal Neoplasms 19Ovarian Neoplasms 16Neoplasms 15Brain Neoplasms 12Lung Neoplasms 11Pancreatic Neoplasms 10Glioma 10Fallopian Tube Neoplasms 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Gliosarcoma 7Adenocarcinoma of Lung 7Kidney Neoplasms 6Liver Neoplasms 5Astrocytoma 5Sarcoma 4Recurrence 4Oligodendroglioma 4Melanoma 4Uterine Cervical Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

pembrolizumab 2Sunitinib 2Cisplatin 2Brentuximab Vedotin 2tremelimumab 1pralsetinib 1keyhole-limpet hemocyanin 1durvalumab 1Tetanus Toxoid 1Sirolimus 1Plicamycin 1Pemetrexed 1Paclitaxel 1Genistein 1Gemcitabine 1Gefitinib 1Erlotinib Hydrochloride 1Epirubicin 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Germ Cell and Embryonal × Bevacizumab × Clear all
NCT02988843 2020-12-10

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
1 enrolled 8 charts

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡